Zacks Small Cap Issues Positive Forecast for HURA Earnings

TuHURA Biosciences (NASDAQ:HURA) – Equities research analysts at Zacks Small Cap increased their Q3 2025 earnings estimates for TuHURA Biosciences in a research report issued to clients and investors on Monday, April 14th. Zacks Small Cap analyst J. Vandermosten now expects that the company will earn ($0.14) per share for the quarter, up from their prior forecast of ($0.15). Zacks Small Cap also issued estimates for TuHURA Biosciences’ Q4 2025 earnings at ($0.14) EPS, Q1 2026 earnings at ($0.15) EPS and Q2 2026 earnings at ($0.15) EPS.

A number of other research analysts have also commented on HURA. RODMAN&RENSHAW upgraded TuHURA Biosciences to a “strong-buy” rating in a report on Thursday, December 19th. Rodman & Renshaw assumed coverage on shares of TuHURA Biosciences in a research note on Thursday, December 19th. They set a “buy” rating and a $11.00 target price for the company. Finally, HC Wainwright decreased their price target on shares of TuHURA Biosciences from $13.00 to $12.00 and set a “buy” rating on the stock in a research report on Thursday, April 3rd.

TuHURA Biosciences Stock Down 2.1 %

NASDAQ HURA opened at $4.11 on Wednesday. The business’s 50-day simple moving average is $3.28. TuHURA Biosciences has a twelve month low of $1.80 and a twelve month high of $7.93.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Accent Capital Management LLC acquired a new position in shares of TuHURA Biosciences in the 4th quarter valued at $29,000. TT Capital Management LLC acquired a new position in TuHURA Biosciences in the fourth quarter worth about $41,000. Jefferies Financial Group Inc. bought a new position in TuHURA Biosciences during the fourth quarter worth about $54,000. Bank of America Corp DE acquired a new stake in TuHURA Biosciences during the fourth quarter valued at approximately $59,000. Finally, Charles Schwab Investment Management Inc. acquired a new stake in TuHURA Biosciences during the fourth quarter valued at approximately $61,000. 0.62% of the stock is owned by institutional investors.

TuHURA Biosciences Company Profile

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.